Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 2, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Cell Membrane-Engineered FePDA Nanoparticles Integrate Ferroptosis and Antitumor Immunity.

Chongqing Chen1, Haitao Wu2, Zijun Jiang3

  • 1Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.

Small (Weinheim an Der Bergstrasse, Germany)
|July 1, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From bench to bedside: new frontiers in brain disorders.

Science China. Life sciences·2026
Same author

Pressure- and frequency-dependent acoustic behavior of second-generation acoustic reporter genes-expressing bacteria for optimized ultrasound imaging.

Ultrasonics·2026
Same author

Reducing write amplification of DM-SMR disks by shingle-aware persistent cache.

Scientific reports·2026
Same author

Polymorphous low-grade neuroepithelial tumor of the young: a case report.

Frontiers in oncology·2026
Same author

Pickering emulsion gels stabilised by ultrasound-treated PSE-like myofibrillar protein microgel particles for age-friendly dysphagia foods: The structural changes, stability and texture-modified gel properties.

Food chemistry·2026
Same author

Dual-center development and validation of a LDL-C and TC based nomogram for preoperative hemorrhagic risk in adult moyamoya disease.

Frontiers in nutrition·2026

This study developed a novel nanoplatform (FePDA-TMOC) that triggers ferroptosis and enhances antitumor immunity for hepatocellular carcinoma (HCC) treatment. It effectively suppresses tumor growth and metastasis by converting "cold" tumors into "hot" ones.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Immunotherapy

Background:

  • Ferroptosis shows potential in cancer therapy but often fails to activate antitumor immunity.
  • Hepatocellular carcinoma (HCC) remains a significant health challenge, necessitating novel therapeutic strategies.
  • Current treatments struggle to overcome immune suppression in the tumor microenvironment.

Purpose of the Study:

  • To develop a targeted nanoplatform for hepatocellular carcinoma (HCC) that combines ferroptosis induction with immune activation.
  • To engineer FePDA nanozymes coated with tumor cell membranes (FePDA-TMOC) for enhanced homologous targeting and immune co-stimulation.
  • To investigate the therapeutic efficacy of FePDA-TMOC in promoting ferroptosis and transforming 'cold' tumors into 'hot' tumors.

Main Methods:

Keywords:
antigen presentationantioxidant defenseferroptosishepatocellular carcinomatumor microenvironment

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Related Experiment Videos

Last Updated: Jul 2, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

  • Construction of FePDA-TMOC nanoparticles using FePDA nanozymes coated with Hepa1-6 cell membranes overexpressing ovalbumin (OVA) and CD40 ligand (CD40L).
  • In vitro assessment of FePDA-TMOC's ability to induce ferroptosis in Hepa1-6 cells and modulate macrophage polarization.
  • In vivo evaluation of FePDA-TMOC's tumor targeting, immune cell infiltration, cytokine levels, tumor suppression, and systemic toxicity following administration in a tumor model.

Main Results:

  • FePDA-TMOC effectively depleted intracellular glutathione (GSH), induced lipid peroxidation, and promoted ferroptosis via the GPX4-SLC7A11 axis.
  • The OVA/CD40L-modified membrane facilitated antigen-presenting cell uptake and enhanced pro-inflammatory immune responses.
  • In vivo studies showed preferential tumor accumulation, increased CD8+ T cell infiltration, elevated pro-inflammatory cytokines, and significant suppression of tumor growth and metastasis without systemic toxicity.

Conclusions:

  • FePDA-TMOC represents a promising nanotherapeutic strategy for HCC by synergistically combining ferroptosis induction with robust antitumor immune activation.
  • This approach effectively converts immune-cold tumors into immune-hot tumors, offering a potential solution for overcoming treatment resistance.
  • The study highlights the potential of homologous targeting and immune co-stimulation via cell membrane-camouflaged nanoparticles in cancer therapy.